References
- Kyle R A. Monoclonal gammapathy of undertermined significance (MGUS): a review. Clinical Haematology 1982; 11: 123–150
- Van de Poel M UW, Coebergh J WW, Hillen H FP. Malignant transformation of MGUS among patients of a community hospital in Southeastern Netherland. British Journal of Haematology 1995; 91: 121–125
- Greipp P R, Kyle R A. Clinical, morphological and cell kinetic differences among MM, MGUS and smoldering MM. Blood 1983; 62: 166–170
- Boccadoro M, Garavatti P, Fossati G, Marmont F, Neretto G, Gallomini A, Volta C, Tribalto M, Testa M G, Amadori S, Mandelli F, Dune B GM. Low plasma cell 3(H) thy‐midine incorporation in MGUS, smoldering myeloma and remission phase myeloma : a reliable indicator of patients not requiring therapy. British Journal of Haematology 1984; 58: 689
- Isaksson E, Bjorkholm M, Holm G, Johansson B, Nilsson B, Mellstedt M, Osterborg A. Blood clonal B‐cell excess in patients with MGUS: association with malignant transformation. British Journal of Haematology 1996; 92: 71–76
- Durie B GM. Staging and kinetics of multiple myeloma. Seminars in Oncology 1986; 13: 300–309
- Kyle R A. Benign monoclonal gammapathy: after 20–30 years of follow‐up. Mayo Clinic Proceedings 1993; 68: 26–36
- Cuzick J, Cooper E M, MacLennan I C. The prognostic value of serum beta2 microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer 1985; 52: 1–6
- Kyle R A, Greipp P R. Idiopathic Bence Jones pro‐teinuria. New England Journal of Medicine 1982; 306: 564–567
- Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C‐reactive protein and beta2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
- Ballester O F, Moscinski L C, Lyman G M, Chaney J V, Saba M I, Spiers A SD, Klein C. High levels of Inerleukin ‐6 are associated with low tumor burder and low growth fraction in MM. Blood 1994; 83: 1903–1908
- Tienhaara A, Pulkii K, Mattile K, Iyaala K, Pellinieni I T. Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with MM at diagnosis. British Journal of Haematology 1994; 86: 391–393